Brii Biosciences Limited announce the appointment of Dr. Brian Alvin Johns, Ph.D., as Chief Scientific Officer, effective January 3, 2024. Dr. Johns will oversee the discovery programs at Brii Bio and set the company's future pipeline strategy and priority. Dr. Johns brings a wealth of experience from the pharmaceutical industry, with a proven track record of successfully building and leading teams in the discovery and early development of novel medicines.

His deep understanding of end-to-end research and development objectives has played a pivotal role in creating and delivering differentiated medicines that have transformed so many patients' lives. Prior to joining Brii Bio, Dr. Johns served as the Chief Scientific Officer at HemoShear Therapeutics Inc., where he led his team to novel targets and platforms in various disease areas. Before that, he was vice president of discovery at ViiV Healthcare and GlaxoSmithKline, where he made huge contributions to ViiV/GSK's HIV franchise with the discovery of groundbreaking medications in dolutegravir and cabotegravir.

Dr. Johns holds a Ph.D. in Chemistry and has received numerous honors and awards for his substantial contributions to the field. His extensive expertise in medicinal chemistry and drug discovery is further highlighted by numerous patents and publications.